- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Interventions
- Pomalidomide, Cyclophosphamide, Dexamethasone
- Drug
- Lead sponsor
- Ajai Chari
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cancer
- Interventions
- aprepitant, dexamethasone, ondansetron, placebo
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Interventions
- GEN3014, Daratumumab
- Biological · Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • Cleveland, Ohio • Milwaukee, Wisconsin
- Conditions
- Relapsed and Refractory Multiple Myeloma
- Interventions
- anitocabtagene-autoleucel
- Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Milwaukee, Wisconsin
- Conditions
- Multiple Myeloma
- Interventions
- rhIL-2, PNK-007
- Drug · Biological
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Minneapolis, Minnesota • St Louis, Missouri • Omaha, Nebraska + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- ONC201, Dexamethasone
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Advanced Hematologic Malignancies
- Interventions
- DSP-5336, [14C]-DSP-5336
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab
- Drug
- Lead sponsor
- Sundar Jagannath
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- TTI-622, Daratumumab Hyaluronidase-fihj
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- Busulfan, Cyclophosphamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 6 Months to 65 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Testicular Germ Cell Tumor
- Interventions
- DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- Talquetamab, Daratumumab
- Drug
- Lead sponsor
- Larysa Sanchez
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Simvastatin
- Other · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Cancer
- Interventions
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
- Biological · Genetic · Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- busulfan, Cyclophosphamide, VP-16, Fractionated Total Body Irradiation (FTBI)
- Drug · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 15 Years to 55 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2007
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Oprozomib, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 17
- States / cities
- Encinitas, California • West Hollywood, California • Whittier, California + 13 more
- Conditions
- Multiple Myeloma
- Interventions
- No intervention
- Other
- Lead sponsor
- Janssen-Cilag Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 12
- States / cities
- Glendale, California • Greenbrae, California • Weeki Wachee, Florida + 9 more
- Conditions
- Multiple Myeloma
- Interventions
- Ganetespib, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more
- Conditions
- Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment
- Interventions
- Total Marrow Irradiation, Melphalan, Filgrastim (G-CSF), Autologous transplant
- Radiation · Drug · Procedure
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- PBCAR269A, Fludarabine, Cyclophosphamide, Nirogacestat
- Genetic · Drug
- Lead sponsor
- Precision BioSciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Duarte, California • San Francisco, California • Boston, Massachusetts + 2 more
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
- Interventions
- AMG 397, Dexamethasone, Azacitidine
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more
- Conditions
- Relapse Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Carfilzomib
- Drug
- Lead sponsor
- Ajai Chari
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity
- Interventions
- Isatuximab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Winston-Salem, North Carolina